FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could this drug stop the body from turning muscle into bone?
Disease control OngoingThis study tests an experimental drug called andecaliximab in 92 children and adults with fibrodysplasia ossificans progressiva (FOP), a rare disease where soft tissues turn into bone. The goal is to see if the drug safely reduces new abnormal bone growth and flare-ups. Participa…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Phase: PHASE2, PHASE3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated May 26, 2026 09:52 UTC
-
Hope for rare bone disease: experimental drug garetosmab enters final testing phase
Disease control OngoingThis study tests an experimental drug called garetosmab in 63 adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition where soft tissues turn into bone. The goal is to see if the drug safely reduces new abnormal bone growth and flare-ups. Participants re…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:53 UTC